SCHEMBL2179929

SCHEMBL2179929

CC(C)[C@@H](C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4cc(Cl)ccc4Oc4ccccc4)cc3)cc2C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SDCBP O00560 4/20 0.46
SDC2 P34741 4/20 0.46
LMNA P02545 2/20 0.45
TP53 P04637 1/20 0.45
IDO1 P14902 2/20 0.45
DGAT1 O75907 2/20 0.45
CSGALNACT1 Q8TDX6 1/20 0.44
ALDH1A1 P00352 1/20 0.44
P2RY1 P47900 1/20 0.42
NPSR1 Q6W5P4 3/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
GRIK1 P39086 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177867 1.00 SDCBP (0.46) SDCBPSDC2LMNATP53IDO1
SCHEMBL2181145 0.94 DGAT1 (0.52) SDCBPSDC2LMNATP53IDO1
SCHEMBL2181137 0.94 DGAT1 (0.52) SDCBPSDC2LMNATP53IDO1
SCHEMBL2178853 0.91 LMNA (0.49) SDCBPSDC2LMNATP53DGAT1
SCHEMBL2180680 0.91 LMNA (0.49) SDCBPSDC2LMNATP53DGAT1
SCHEMBL2180786 0.88 DGAT1 (0.49) SDCBPSDC2LMNATP53IDO1
SCHEMBL2355332 0.88 DGAT1 (0.49) SDCBPSDC2LMNATP53IDO1
SCHEMBL2178235 0.88 LMNA (0.53) SDCBPSDC2LMNATP53CYP2C9
SCHEMBL2179239 0.88 LMNA (0.53) SDCBPSDC2LMNATP53CYP2C9
SCHEMBL2355335 0.86 DGAT1 (0.48) SDCBPSDC2LMNATP53IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT SDCBP 2373/4885SDC2 3855/4885LMNA 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.